News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
25,488 Results
Type
Article (3356)
Company Profile (1)
Press Release (22009)
Multimedia
Podcasts (25)
Webinars (1)
Section
Business (8976)
Career Advice (75)
Deals (1092)
Drug Delivery (15)
Drug Development (4154)
Employer Resources (7)
FDA (727)
Job Trends (708)
News (13583)
Policy (1075)
Tag
Academia (77)
Accelerated approval (4)
ADA (7)
Adcomms (1)
Allergies (9)
Alliances (2091)
Alzheimer's disease (141)
Antibody-drug conjugate (ADC) (38)
Approvals (738)
Artificial intelligence (42)
ASCO (23)
Autoimmune disease (17)
Automation (5)
Bankruptcy (6)
Best Places to Work (500)
BIO (1)
Biosimilars (16)
BioSpace Insights (5)
Biotechnology (1)
Bladder cancer (10)
Brain cancer (6)
Breast cancer (75)
Cancer (395)
Cardiovascular disease (19)
Career advice (70)
Career pathing (2)
CAR-T (6)
CDC (3)
Cell therapy (38)
Cervical cancer (7)
Clinical research (3407)
Collaboration (152)
Company closure (1)
Compensation (4)
Complete response letters (10)
COVID-19 (218)
C-suite (100)
Cystic fibrosis (2)
Data (285)
Depression (5)
Diabetes (28)
Diagnostics (293)
Digital health (2)
Diversity, equity & inclusion (1)
Drug discovery (16)
Drug pricing (8)
Drug shortages (4)
Duchenne muscular dystrophy (28)
Earnings (2197)
Editorial (7)
Employer branding (4)
Employer resources (6)
Events (2335)
Executive appointments (73)
FDA (866)
Funding (80)
Gene editing (3)
Generative AI (3)
Gene therapy (41)
GLP-1 (86)
Government (204)
Guidances (7)
Healthcare (526)
Hematology (12)
HIV (6)
Huntington's disease (16)
IgA nephropathy (2)
Immunology and inflammation (35)
Immuno-oncology (6)
Indications (6)
Infectious disease (231)
Inflammatory bowel disease (15)
Inflation Reduction Act (1)
Influenza (9)
Intellectual property (3)
Interviews (7)
IPO (339)
IRA (1)
Job creations (219)
Job search strategy (61)
JPM (11)
Labor market (6)
Layoffs (61)
Leadership (4)
Legal (214)
Licensing (1)
Liver cancer (15)
Longevity (3)
Lung cancer (65)
Lymphoma (54)
Machine learning (2)
Management (1)
Manufacturing (75)
MASH (12)
Medical device (179)
Medtech (182)
Mergers & acquisitions (782)
Metabolic disorders (134)
mRNA (14)
Multiple sclerosis (37)
NASH (1)
Neurodegenerative disease (45)
Neuropsychiatric disorders (10)
Neuroscience (245)
Neurotech (1)
NextGen: Class of 2026 (198)
Non-profit (158)
Now hiring (6)
Obesity (99)
Opinion (25)
Ovarian cancer (6)
Pain (3)
Pancreatic cancer (11)
Parkinson's disease (18)
Partnered (1)
Patents (13)
Patient recruitment (17)
Peanut (3)
People (3667)
Pharmacy benefit managers (1)
Phase 1 (1024)
Phase 2 (1396)
Phase 3 (1426)
Pipeline (369)
Policy (18)
Postmarket research (195)
Preclinical (319)
Press Release (1)
Prostate cancer (8)
Psychedelics (6)
Radiopharmaceuticals (14)
Rare diseases (47)
Real estate (184)
Recruiting (4)
Regulatory (923)
Reports (6)
Research institute (97)
Resumes & cover letters (11)
Rett syndrome (2)
RNA editing (1)
RSV (4)
Schizophrenia (6)
Series A (18)
Series B (15)
Sickle cell disease (2)
Special edition (6)
Spinal muscular atrophy (60)
Sponsored (1)
Startups (188)
Stomach cancer (5)
Supply chain (8)
Tariffs (26)
The Weekly (25)
Vaccines (48)
Venture capital (14)
Weight loss (63)
Women's health (3)
Date
Today (4)
Last 7 days (23)
Last 30 days (82)
Last 365 days (939)
2026 (622)
2025 (958)
2024 (1200)
2023 (1259)
2022 (2625)
2021 (2288)
2020 (2037)
2019 (1381)
2018 (1166)
2017 (1077)
2016 (1005)
2015 (1327)
2014 (926)
2013 (758)
2012 (915)
2011 (1033)
2010 (1000)
Location
Africa (55)
Alabama (2)
Arizona (17)
Asia (1257)
Australia (181)
California (465)
Canada (69)
China (77)
Colorado (3)
Connecticut (11)
Delaware (2)
Europe (4748)
Florida (18)
Georgia (3)
Illinois (37)
India (3)
Indiana (25)
Japan (14)
Kentucky (2)
Louisiana (1)
Maryland (17)
Massachusetts (306)
Michigan (10)
Minnesota (37)
Nevada (3)
New Jersey (60)
New York (142)
North Carolina (33)
Northern California (289)
Ohio (2)
Oregon (1)
Pennsylvania (30)
Rhode Island (2)
South America (50)
Southern California (130)
Tennessee (1)
Texas (31)
United States (1304)
Utah (15)
Vermont (1)
Virginia (6)
Washington D.C. (2)
Washington State (86)
Wisconsin (3)
25,488 Results for "roche".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Huntington’s disease
Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO
The failure of Roche’s Ionis-partnered tominersen in Huntington’s disease may indicate that Wave Life Sciences’ allele-specific antisense oligonucleotide candidate WVE-003 is on the right track, according to analysts at Rodman & Renshaw.
July 13, 2026
·
4 min read
·
Heather McKenzie
Huntington’s disease
Roche scraps 2 Huntington’s studies, handing Ionis more bad news
Roche’s decision to discontinue the Ionis-partnered trials came soon after the biotech sustained a late-stage failure in ATTR-CM.
July 10, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Roche pours $750M into Oregon manufacturing plant as obesity push expands
After committing $2 billion to a new North Carolina facility to boost capacity for its next-gen obesity candidates, Roche’s Genentech is putting down more cash to expand a device fill-finish site in Oregon.
August 20, 2026
·
1 min read
·
Gabrielle Masson
Rare diseases
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
Oak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
July 28, 2026
·
2 min read
·
Tristan Manalac
Obesity
Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug
Roche, through its subsidiary Genentech, will gain access to the investigational asset HM17321, which is designed to not only elicit weight loss but also improve lean mass.
August 24, 2026
·
2 min read
·
Tristan Manalac
Inflammatory bowel disease
Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms
Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.
June 23, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Roche’s US subsidiary Genentech announces manufacturing expansion in the United States
August 20, 2026
·
3 min read
Obesity
Roche cans one Carmot obesity asset as another shows best-in-class potential
Acmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcomes. Both assets come from the $2.7 billion buy of Carmot Therapeutics.
July 24, 2026
·
2 min read
·
Tristan Manalac
Earnings
Roche’s late stage pipeline ‘so full,’ CEO Schinecker not feeling pressure to add on
Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker said on the pharma’s Q2 earnings call.
July 23, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
May 21, 2026
·
2 min read
·
Nick Paul Taylor
1 of 2,549
Next
